MedTrace Logo

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

NCT06712082 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to learn if the study medicine (called PF-07264660) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who:

* are between 18 to 65 years of age.
* are Chinese participants who are overtly healthy as determined by medical evaluation.
* have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds).

All participants in this study will receive study medicine. Three-fourths will receive PF-07264660 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time.

The study will compare the experiences of people receiving PF-07264660 to those of people who do not. This will help see if PF-07264660 is safe and how it behaves inside the human body.

Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.

Conditions

  • Healthy

Interventions

DRUG

PF-07264660

PF-07264660 solution for injection (single use only)

OTHER

Placebo

Placebo solution for injection (single use only)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-09-04
Completion
2025-09-04
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06712082 on ClinicalTrials.gov